Business
Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that its Chief Medical Officer, Dr. Carman Giacomantonio presented data from its first-in-human early feasibility study for its Targeted Hyperthermia Therapy cancer treatment at the American Association for Cancer Research ("AACR") last week in San Diego. Dr. Giacomantonio has also been accepted to present Sona's data at the American Society of Clinical Oncology ("ASCO") annual meeting May 29 – June 2, 2026, a confe
About this update from Sona Nanotech, Inc.
[{"type":"text","content":"/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/","length":109,"tagName":"p","attribs":{}},{"type":"text","content":"HALIFAX, NS, April 27, 2026 /CNW/ - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that its Chief Medical Officer, Dr. Carman Giacomantonio presented data from its first-in-human early feasibility study for its Targeted Hyperthermia Therapy cancer treatment at the American Association for Cancer Research ("AACR") last week in San Diego. Dr. Giacomantonio has also been accepted to present Sona's data at the American Society of Clinical Oncology ("ASCO") annual meeting May 29 – June 2, 2026, a conference centered on scientific innovation and its translation into practical patient-centered clinical application.","length":713,"tagName":"p"},{"type":"image","alt":"Sona Nanotech logo (CNW Group/Sona Nanotech Inc.)","displaySize":"","headline":null,"caption":"Sona Nanotech logo (CNW Group/Sona Nanotech Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":335,"url":"https://media.zenfs.com/en/cnwgroup.com/500970b3a5af9625b712074f2965afce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i_AceVpnWt445Rnm1SquGA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTU5MA--/https://media.zenfs.com/en/cnwgroup.com/500970b3a5af9625b712074f2965afce","width":400,"height":335}},"href":"https://mma.prnewswire.com/media/2965990/Sona_Nanotech_Inc__Sona_Nanotech_Showcases_Cancer_Therapy_Result.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Giacomantonio commented, "AACR is the premier stage for sharing breakthrough science, and it was exciting to see our Targeted Hyperthermia Therapy align so well with the conference's focus on overcoming immunotherapy resistance. The feedback we received on our clinical study was incredibly encouraging and confirms for us that we're on the right path toward offering new hope to patients who have run out of options. Next, we are delighted to have been invited to share our compelling data to the more industry-focused ASCO conference."","length":559,"tagName":"p"},{"type":"text","content":"The presentation highlights the initial safety, tolerability and anti-tumor activity from th...